News Releases

25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to $10 Million Credit Line in 2022 Tildacerfont Patent Portfolio Estate Expanded with Key Method of Use Patents Libbie Mansell

SAN FRANCISCO --(BUSINESS WIRE)--May 3, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will

SAN FRANCISCO --(BUSINESS WIRE)--Apr. 11, 2022-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell , Ph.D.,

Topline Safety Data from Cohort 1 of Phase 2 Pediatric Classic CAH Study Expected by 1H 2023 Will Charlton , M.D., M.A.S., Appointed Chief Medical Officer SAN FRANCISCO --(BUSINESS WIRE)--Mar. 14, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on

SAN FRANCISCO --(BUSINESS WIRE)--Mar. 14, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Will Charlton , M.D.,

SAN FRANCISCO --(BUSINESS WIRE)--Mar. 1, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will

SAN FRANCISCO --(BUSINESS WIRE)--Feb. 3, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg , M.D.,

Topline Data from CAHmelia-203 and CAHmelia-204 Anticipated in 2H 2023 and 2H 2024, Respectively Strategic Reprioritization Extends Anticipated Cash Runway by 6 Months into Q2 2024 CAHmelia Program in Adult Classic CAH to Significantly Expand Sites Globally, Planned Increase of Up to 50 New Sites

– Samir Gharib , MBA, Promoted to President – SAN FRANCISCO --(BUSINESS WIRE)--Jan. 5, 2022-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,